<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Endosc Int Open</journal-id><journal-id journal-id-type="iso-abbrev">Endosc Int Open</journal-id><journal-id journal-id-type="doi">10.1055/s-00025476</journal-id><journal-title-group><journal-title>Endoscopy International Open</journal-title></journal-title-group><issn pub-type="ppub">2364-3722</issn><issn pub-type="epub">2196-9736</issn><publisher><publisher-name>&#x000a9; Georg Thieme Verlag KG</publisher-name><publisher-loc>Stuttgart &#x000b7; New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27747282</article-id><article-id pub-id-type="pmc">5063645</article-id><article-id pub-id-type="doi">10.1055/s-0042-115172</article-id><article-categories><subj-group><subject>Original article</subject></subj-group></article-categories><title-group><article-title>Intravenous injection of low-dose flurbiprofen axetil for preventing post-ERCP pancreatitis in high-risk patients: An interim analysis of the trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fujita</surname><given-names>Yuji</given-names></name><xref rid="AF398-1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Hasegawa</surname><given-names>Sho</given-names></name><xref rid="AF398-1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Kato</surname><given-names>Yuri</given-names></name><xref rid="AF398-1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Ishii</surname><given-names>Ken</given-names></name><xref rid="AF398-1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Iwasaki</surname><given-names>Akito</given-names></name><xref rid="AF398-1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Sato</surname><given-names>Takamitsu</given-names></name><xref rid="AF398-1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Sekino</surname><given-names>Yusuke</given-names></name><xref rid="AF398-1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Hosono</surname><given-names>Kunihiro</given-names></name><xref rid="AF398-1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Nakajima</surname><given-names>Atsushi</given-names></name><xref rid="AF398-1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Kubota</surname><given-names>Kensuke</given-names></name><xref rid="AF398-1" ref-type="aff"/><xref rid="CO398-1" ref-type="author-notes"/></contrib></contrib-group><aff id="AF398-1"><institution>Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan</institution></aff><author-notes><corresp id="CO398-1"><bold>Corresponding author </bold>Kensuke Kubota <phone>81 457872800</phone><fax>+81 457872866</fax><email>kubotak@yokohama-cu.ac.jp</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>21</day><month>9</month><year>2016</year></pub-date><volume>4</volume><issue>10</issue><fpage>E1078</fpage><lpage>E1082</lpage><history><date date-type="received"><day>25</day><month>9</month><year>2015</year></date><date date-type="accepted"><day>29</day><month>7</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Thieme Medical Publishers</copyright-statement></permissions><abstract><p>
<bold>Background and study aims:</bold> Several meta-analyses and randomized control trials have demonstrated the efficacy of rectal nonsteroidal anti-inflammatory drugs for preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). Diclofenac or indomethacin was administered at a dose of 100&#x0200a;mg in those studies, which may be too high for Asian population. In addition, rectal administration can be considered complicated.</p><p>
<bold>Patients and methods: </bold>This study was a prospective, randomized, placebo-controlled trial. Patients with a PEP risk score &#x02265;&#x0200a;1 were randomly assigned to receive intravenous injection of 50&#x0200a;mg flurbiprofen axetil (flurbiprofen group) or saline only (placebo group). The primary outcome was reduced PEP. The secondary outcome was amylase level after 2 hours of ERCP as a predictor of PEP. (Clinical Trials.gov, ID UMIN000011322)</p><p>
<bold>Results:</bold> In total, 144 patients were enrolled from August 2013 to March 2015. We performed an interim analysis of the first 100 patients: 47 received flurbiprofen axetil and 53 received placebo. PEP occurred in 11 patients (11&#x0200a;%): 2 of 47 (4.3&#x0200a;%) in the flurbiprofen group and 9 of 53 (17&#x0200a;%) in the placebo group (<italic>P</italic>&#x0200a;=&#x0200a;0.042). Relative risk reduction was 62.4&#x0200a;%. Hyperamylasemia did not differ significantly (17.0&#x0200a;% vs. 26.4&#x0200a;%, <italic>P</italic>&#x0200a;=&#x0200a;0.109). This analysis resulted in early termination of the study for ethical reasons.</p><p>
<bold>Conclusions: </bold>Intravenous injection of low-dose flurbiprofen axetil after ERCP can reduce the incidence of PEP in high-risk patients</p></abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Acute pancreatitis is the most common adverse event (AE) associated with endoscopic retrograde cholangiopancreatography (ERCP). Post-ERCP pancreatitis (PEP) occurs in 1&#x0200a;% to 10&#x0200a;% of patients <xref rid="JR398-1" ref-type="bibr">1</xref>
<xref rid="JR398-2" ref-type="bibr">2</xref>
<xref rid="JR398-3" ref-type="bibr">3</xref>, and in 17&#x0200a;% to 40&#x0200a;% of high-risk patients <xref rid="JR398-4" ref-type="bibr">4</xref>
<xref rid="JR398-5" ref-type="bibr">5</xref>
<xref rid="JR398-6" ref-type="bibr">6</xref>. Most cases of PEP are mild or moderate, but severe pancreatitis, including that requiring endoscopic intervention, occurs in 0.4&#x0200a;% to 0.6&#x0200a;% of those cases <xref rid="JR398-7" ref-type="bibr">7</xref>
<xref rid="JR398-8" ref-type="bibr">8</xref>. Nonsteroidal anti-inflammatory drugs (NSAIDs) are inhibitors of phospholipase A2, which is believed to have a pivotal role in the initial inflammatory cascade of acute pancreatitis <xref rid="JR398-9" ref-type="bibr">9</xref>
<xref rid="JR398-10" ref-type="bibr">10</xref>
<xref rid="JR398-11" ref-type="bibr">11</xref>. Several randomized controlled trials <xref rid="JR398-12" ref-type="bibr">12</xref>
<xref rid="JR398-13" ref-type="bibr">13</xref>
<xref rid="JR398-14" ref-type="bibr">14</xref>
<xref rid="JR398-15" ref-type="bibr">15</xref> have confirmed the efficacy of rectal NSAIDs for prevention of PEP. However, in those studies, diclofenac or indomethacin was used at a dose of 100&#x0200a;mg, which is higher than the usual dose in Asia; furthermore, rectal administration may be considered complicated. Intravenous injection of NSAIDs is technically easy for patients. It is desirable to minimize the dose of NSAIDs because of potent side effects <xref rid="JR398-6" ref-type="bibr">6</xref>. Therefore, we conducted a randomized controlled clinical trial to evaluate the efficacy and safety of intravenous injection of low-dose flurbiprofen axetil for preventing PEP in high-risk patients.</p></sec><sec sec-type="methods"><title>Patients and methods</title><sec><title>Study design</title><p>This study was prospective, randomized, and placebo-controlled. It was approved by the Institutional Review Boards before initiation of the study, and was registered (ClinicalTrials.gov, ID UMIN000011322).</p></sec><sec><title>Patients</title><p>Patients who were scheduled to undergo ERCP were included. All patients had a PEP risk score of &#x02265;&#x0200a;1 in a previous study <xref rid="JR398-6" ref-type="bibr">6</xref>
<xref rid="JR398-16" ref-type="bibr">16</xref> (<xref rid="TB398-1" ref-type="table">Table&#x0200a;1</xref>). Patients were excluded for any of the following reasons: (1) acute or active pancreatitis; (2) metallic stent inserted across the papilla; (3) history of endoscopic sphincterotomy; (4) peptic ulcer diseases; (5) aspirin-induced asthma; (6) NSAIDs during the preceding 1 week; (7) hypersensitivity to NSAIDs; (8) pregnancy or breastfeeding; (9) severe renal dysfunction; or (10) patients whom the doctor in attendance judged to be unsuitable for inclusion. Patients were randomly assigned to receive intravenous (IV) injection of 50&#x0200a;mg flurbiprofen axetil with 20&#x0200a;mL saline (flurbiprofen group), or IV injection of 20&#x0200a;mL saline only (placebo group). The dose of flurbiprofen axetil was reduced to 25&#x0200a;mg in patients whose body weight was &#x0003c;&#x0200a;50&#x0200a;kg. Flurbiprofen axetil was injected IV immediately after ERCP while a patient was still in the procedure room. All patients received antibiotics (Sulbactam/Ampicillin 1&#x0200a;g&#x0200a;&#x000d7;&#x0200a;2) and protease inhibitor (10&#x0200a;mg nafamostat mesilate). Randomization was performed using a random number table. Endoscopists and patients were blinded to the treatment group allocation. A total of 100 patients were randomized. ERCP was performed by 3 skilled endoscopists who each perform 200 to 300 ERCP procedures annually. We used a 15-degree backward-oblique angle duodenoscope with an elevator function (JF-260V, or TJF-260V; Olympus Medical Systems Corp, Tokyo, Japan). After the duodenal papilla had been viewed from the front, selective cannulation was attempted using a conventional catheter (PR-104Q-1; Olympus) by contrast-assisted method. If 3 attempts at contrast-assisted cannulation of the pancreatic duct were unsuccessful, wire-guided cannulation (WGC) was attempted instead using a 0.035-inch guidewire (Jagwire, angle type; Boston Scientific, Boston, MA, USA). If cannulation by WGC was unsuccessful, precut was performed. </p><table-wrap id="TB398-1"><label><bold>Table&#x0200a;1</bold></label><caption><title>Major and minor study inclusion criteria used to calculate PEP risk score.</title></caption><table rules="all"><col width="54*"/><col width="46*"/><thead><tr><td>Major criteria (1 point)</td><td>Minor criteria (0.5 point)</td></tr></thead><tbody><tr><td valign="top" align="left">Clinical suspicion of sphincter of Oddi dysfunction</td><td valign="top" align="left">Age&#x0200a;&#x0003c;&#x0200a;50 years and female</td></tr><tr><td valign="top" align="left">History of PEP</td><td valign="top" align="left">History of recurrent pancreatitis</td></tr><tr><td valign="top" align="left">Pancreatic sphincterotomy</td><td valign="top" align="left">&#x02265;&#x0200a;3 pancreatic injection, with at least one injection to tail</td></tr><tr><td valign="top" align="left">Pre-cut sphincterotomy</td><td valign="top" align="left">Pancreatic acinarization</td></tr><tr><td valign="top" align="left">&#x0003e;&#x0200a;8 Cannulation attempt</td><td valign="top" align="left">Pancreatic brush cytology</td></tr><tr><td valign="top" align="left">Pneumatic dilation of intact biliary sphincter</td><td valign="top" align="left"/></tr><tr><td valign="top" align="left">Ampullectomy</td><td valign="top" align="left"/></tr></tbody></table></table-wrap></sec><sec><title>Study outcomes</title><p>The primary outcome of the study was the development of PEP, which was defined according to the criteria of Cotton et al. <xref rid="JR398-1" ref-type="bibr">1</xref>. PEP was diagnosed if there was new onset of pain in the upper abdomen and elevation of serum amylase level to &#x0003e;&#x0200a;3 times the upper limit of normal within 24 hours after ERCP, and prolonged hospitalization for &#x02265;&#x0200a;2 days. The severity of pancreatitis was graded as mild when hospitalization lasted 2 to 3 days, moderate for 4 to 10 days, and severe when prolonged for &#x0003e;&#x0200a;10 days or any of the following occurred: hemorrhagic pancreatitis, pancreatic necrosis, pancreatic pseudocyst, or a need for percutaneous drainage or surgery. The secondary outcome was serum amylase level at 2 hours after ERCP as a predictor of PEP.</p></sec><sec><title>Sample size and statistical analysis</title><p>We planned a prospective, randomized, placebo-controlled trial. Prior data indicate that the PEP rate among controls is 0.18 <xref rid="JR398-6" ref-type="bibr">6</xref>
<xref rid="JR398-17" ref-type="bibr">17</xref>. If the true PEP rate is 0.04 with reference to previous studies <xref rid="JR398-6" ref-type="bibr">6</xref>
<xref rid="JR398-17" ref-type="bibr">17</xref>, we would have needed 182 patients to be able to reject the null hypothesis that the PEP rates for experimental and control subjects were equal with probability (power) 0.8. Type I error probability associated with this test of the null hypothesis was 0.05. We used an Fisher&#x02019;s exact test to evaluate this null hypothesis. Categorical variables were analyzed with &#x003c7;<sup>2 </sup>test, Fisher&#x02019;s exact test and Mann&#x02013;Whitney U-test, as appropriate, while continuous variables were analyzed using Student&#x02019;s <italic>t</italic> test. Risk factors for PEP were examined by univariate and multivariate analyses and calculated with odds ratio (OR) with 95&#x0200a;% confidence interval (CI), using a logistic regression method. Statistical significance was set at <italic>P</italic>&#x0200a;&#x0003c;&#x0200a;0.05. Statistical analysis was performed using the Excel-Toukei 2010 for Windows (Social Survey Research Information, Tokyo, Japan).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Patients and discontinuation</title><p>From August 2013 to March 2015, a total of 144 patients were enrolled (<xref rid="FI398-1" ref-type="fig">Fig.&#x0200a;1</xref>). In March 2015, we performed an interim analysis that has not been preplanned at the first 100 patients and recommended early termination of the study on the basis of the benefit of flurbiprofen axetil as compared with placebo for ethical reasons. A total of 47 patients received flurbiprofen axetil, and 53 received placebo (<xref rid="FI398-1" ref-type="fig">Fig.&#x0200a;1</xref>). All patients completed follow-up to the primary and secondary endpoints. Baseline characteristics and indications for ERCP were similar in the 2 groups (<xref rid="TB398-2" ref-type="table">Table&#x0200a;2</xref> and <xref rid="TB398-3" ref-type="table">Table&#x0200a;3</xref>). </p><fig id="FI398-1"><label>Fig.&#x0200a;1</label><caption><p>
&#x02003;Patient flow diagram.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10-1055-s-0042-115172-i398ei1"/></fig><table-wrap id="TB398-2"><label><bold>Table&#x0200a;2</bold></label><caption><title>Patient characteristics 2at baseline.</title></caption><table rules="all"><col width="58*"/><col width="18*"/><col width="16*"/><col width="13*"/><thead><tr><td>Characteristic</td><td>Flurbiprofen(N&#x0200a;=&#x0200a;47)</td><td>Placebo(N&#x0200a;=&#x0200a;53)</td><td>
<italic>P</italic> value</td></tr></thead><tbody><tr><td valign="middle" align="left">Age</td><td valign="middle" align="left">65.2</td><td valign="middle" align="left">68.1</td><td valign="middle" align="left">0.253</td></tr><tr><td valign="middle" align="left">Female (%)</td><td valign="middle" align="left">12 (25.5)</td><td valign="middle" align="left">16 (30.2)</td><td valign="middle" align="left">0.604</td></tr><tr><td valign="middle" align="left">Younger age (&#x0003c;&#x0200a;50 years)</td><td valign="middle" align="left">5 (10.6)</td><td valign="middle" align="left">3 (5.7)</td><td valign="middle" align="left">0.585</td></tr><tr><td valign="middle" align="left">Naive pappila (%)</td><td valign="middle" align="left">18 (38.3)</td><td valign="middle" align="left">24 (45.3)</td><td valign="middle" align="left">0.480</td></tr><tr><td valign="middle" align="left">Clinical suspicion of sphincter of Oddi dysfunction</td><td valign="middle" align="left">0</td><td valign="middle" align="left">0</td><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left">History of post-ERCP pancreatitis (%)</td><td valign="middle" align="left">1 (2.1)</td><td valign="middle" align="left">1 (1.9)</td><td valign="middle" align="left">0.528</td></tr><tr><td valign="middle" align="left">Difficult cannulation &#x0003e;&#x0200a;8 attempt (%)</td><td valign="middle" align="left">32 (68.1)</td><td valign="middle" align="left">34 (64.2)</td><td valign="middle" align="left">0.679</td></tr><tr><td valign="middle" align="left">Pre-cut sphincterotomy (%)</td><td valign="middle" align="left">0</td><td valign="middle" align="left">2 (3.8)</td><td valign="middle" align="left">0.529</td></tr><tr><td valign="middle" align="left">Pancreatography &#x0003e;&#x0200a;3 times (%)</td><td valign="middle" align="left">24 (51.1)</td><td valign="middle" align="left">24 (45.3)</td><td valign="middle" align="left">0.564</td></tr><tr><td valign="middle" align="left">Therapeutic pancreatic sphincterotomy (%)</td><td valign="middle" align="left">0</td><td valign="middle" align="left">1 (1.9)</td><td valign="middle" align="left">0.952</td></tr><tr><td valign="middle" align="left">Pancreatic acinarization (%)</td><td valign="middle" align="left">12 (25.5)</td><td valign="middle" align="left">10 (18.9)</td><td valign="middle" align="left">0.422</td></tr><tr><td valign="middle" align="left">Therapeutic biliary balloon dilation (%)</td><td valign="middle" align="left">7 (14.9)</td><td valign="middle" align="left">12 (22.6)</td><td valign="middle" align="left">0.324</td></tr><tr><td valign="middle" align="left">Ampullectomy (%)</td><td valign="middle" align="left">4 (8.5)</td><td valign="middle" align="left">3 (5.7)</td><td valign="middle" align="left">0.869</td></tr><tr><td valign="middle" align="left">Brush cytology (%)</td><td valign="middle" align="left">1 (2.1)</td><td valign="middle" align="left">0</td><td valign="middle" align="left">0.952</td></tr><tr><td valign="middle" align="left">Placement of pancreatic stent (%)</td><td valign="middle" align="left">11 (23.4)</td><td valign="middle" align="left">10 (18.9)</td><td valign="middle" align="left">0.578</td></tr><tr><td valign="middle" align="left">Sphincterotomy (%)</td><td valign="middle" align="left">9 (19.1)</td><td valign="middle" align="left">4 (7.5)</td><td valign="middle" align="left">0.085</td></tr><tr><td valign="middle" align="left">PEP score (%)</td><td valign="middle" align="left"/><td valign="middle" align="left"/><td valign="middle" align="left">
<bold>0.522</bold>
</td></tr><tr><td valign="middle" align="left">&#x02003;1.0</td><td valign="middle" align="left">25 (53.2)</td><td valign="middle" align="left">33 (62.3)</td><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left">&#x02003;1.5</td><td valign="middle" align="left">11 (23.4)</td><td valign="middle" align="left">9 (17.0)</td><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left">&#x02003;2.0</td><td valign="middle" align="left">10 (21.3)</td><td valign="middle" align="left">6 (11.3)</td><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left">&#x02003;2.5</td><td valign="middle" align="left">0</td><td valign="middle" align="left">5 (9.4)</td><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left">&#x02003;3.0</td><td valign="middle" align="left">1 (4.7)</td><td valign="middle" align="left">0</td><td valign="middle" align="left"/></tr></tbody></table></table-wrap><table-wrap id="TB398-3"><label><bold>Table&#x0200a;3</bold></label><caption><title>Indications for ERCP in the flurbiprofen axetil and placebo groups.</title></caption><table rules="all"><col width="50*"/><col width="20*"/><col width="14*"/><col width="14*"/><thead><tr><td/><td>Flurbiprofen(N&#x0200a;=&#x0200a;47)</td><td>Placebo(N&#x0200a;=&#x0200a;53)</td><td>
<italic>P</italic> value</td></tr></thead><tbody><tr><td valign="top" align="left">Biliary stone</td><td valign="top" align="left">12</td><td valign="top" align="left">17</td><td valign="top" align="left">0.472</td></tr><tr><td valign="top" align="left">Biliary tract cancer</td><td valign="top" align="left">11</td><td valign="top" align="left">&#x02007;8</td><td valign="top" align="left">0.290</td></tr><tr><td valign="top" align="left">Intraductal papillary mucinous neoplasm</td><td valign="top" align="left">&#x02007;4</td><td valign="top" align="left">&#x02007;2</td><td valign="top" align="left">0.566</td></tr><tr><td valign="top" align="left">Pancreatic cancer</td><td valign="top" align="left">&#x02007;5</td><td valign="top" align="left">&#x02007;9</td><td valign="top" align="left">0.362</td></tr><tr><td valign="top" align="left">Chronic pancreatitis</td><td valign="top" align="left">&#x02007;8</td><td valign="top" align="left">&#x02007;8</td><td valign="top" align="left">0.793</td></tr><tr><td valign="top" align="left">Ampullary tumor</td><td valign="top" align="left">&#x02007;4</td><td valign="top" align="left">&#x02007;3</td><td valign="top" align="left">0.869</td></tr><tr><td valign="top" align="left">Others</td><td valign="top" align="left">&#x02007;3</td><td valign="top" align="left">&#x02007;6</td><td valign="top" align="left">0.609</td></tr></tbody></table></table-wrap></sec><sec><title>Study outcomes</title><p>The primary outcome of PEP occurred in 11 of 100 patients (11&#x0200a;%): 2 of 47 patients (4.3&#x0200a;%) in the flurbiprofen group and 9e of 53 patients (17&#x0200a;%) in the placebo group.&#x0200a;The incidence of PEP was lower in the flurbiprofen group (<italic>P</italic>&#x0200a;=&#x0200a;0.041). In addition, all instances of PEP in the flurbiprofen group were mild. However, in the placebo group, PEP was mild in 6 patients and moderate in 3 (<xref rid="FI398-2" ref-type="fig">Fig.&#x0200a;2</xref>). Absolute risk reduction was 12.7&#x0200a;% and the number needed to treat (NNT) was 7.9. Relative risk reduction (RRR) was 62.4. </p><fig id="FI398-2"><label>Fig.&#x0200a;2</label><caption><p>
&#x02003;Incidence of the primary and secondary outcomes. <bold>a</bold> Incidence of post-ERCP pancreatitis and severity in the two groups. <bold>b</bold> Incidence of hyperamylasemia in the two groups.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10-1055-s-0042-115172-i398ei2"/></fig><p>The secondary outcome, hyperamylasemia at 2 hours after ERCP, was observed in 22 of 100 patients (22&#x0200a;%): 8 of 47 patients (17.0&#x0200a;%) in the flurbiprofen group and 14 of 53 patients (26.4&#x0200a;%) in the placebo group (<italic>P</italic>&#x0200a;=&#x0200a;0.109) (<xref rid="FI398-2" ref-type="fig">Fig.&#x0200a;2</xref>). No AEs related to flurbiprofen axetil were reported.</p><p>The relative benefit of flurbiprofen axetil differed according to PEP risk score. With a risk score of 1 or 1.5 points, PEP occurred in 1 of 36 (2.8&#x0200a;%) patients and 7 of 42 (16.7) patients, respectively (<italic>P</italic>&#x0200a;=&#x0200a;0.047). The RRR was 83.3&#x0200a;% and NNT was 7.2. In contrast, in patients with a risk score &#x0003e;&#x0200a;2 points, PEP was noted in 1 of 11 (9.1&#x0200a;%) patients and 2 of 11 (18.2) patients, and RRR was 50 and NNT was 11. There was no significant difference between the 2 groups (<italic>P</italic>&#x0200a;=&#x0200a;0.500) (<xref rid="TB398-4" ref-type="table">Table&#x0200a;4</xref>). Following multivariate logistic regression analysis, IV injection of flurbiprofen axetil was the only significant independent risk factor for occurrence of PEP (OR: 0.185, 95&#x0200a;% CI: 0.036&#x0200a;&#x02013;&#x0200a;0.967) (<xref rid="TB398-5" ref-type="table">Table&#x0200a;5</xref>).</p><table-wrap id="TB398-4"><label><bold>Table&#x0200a;4</bold></label><caption><title>Analysis of treatment effect.</title></caption><table rules="all"><col width="25*"/><col width="18*"/><col width="18*"/><col width="18*"/><col width="10*"/><col width="10*"/><thead><tr><td/><td>Flurbiprofen</td><td>Placebo</td><td>Relative risk reduction (%)</td><td>NNT</td><td>
<italic>P</italic> value</td></tr></thead><tbody><tr><td valign="middle" align="left">PEP risk score</td><td valign="middle" align="left"/><td valign="middle" align="left"/><td valign="middle" align="left"/><td valign="middle" align="left"/><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left">Any score</td><td valign="middle" align="left">2/47 (4.3)</td><td valign="middle" align="left">9/53 (17.0)</td><td valign="middle" align="left">62.4</td><td valign="middle" align="left">7.9</td><td valign="middle" align="left">0.041</td></tr><tr><td valign="middle" align="left">1 or 1.5</td><td valign="middle" align="left">1/36 (2.8)</td><td valign="middle" align="left">7/42 (16.7)</td><td valign="middle" align="left">83.3</td><td valign="middle" align="left">7.2</td><td valign="middle" align="left">0.047</td></tr><tr><td valign="middle" align="left">&#x02265;&#x0200a;2</td><td valign="middle" align="left">1/11 (9.1)</td><td valign="middle" align="left">2/11 (18.2)</td><td valign="middle" align="left">50</td><td valign="middle" align="left">11</td><td valign="middle" align="left">0.500</td></tr></tbody></table></table-wrap><table-wrap id="TB398-5"><label><bold>Table&#x0200a;5</bold></label><caption><title>Univariate and multivariate analyses for identification of independent risk factors for PEP.</title></caption><table rules="all"><col width="33*"/><col width="10*"/><col width="13*"/><col width="10*"/><col width="10*"/><col width="12*"/><col width="7*"/><thead><tr><td>Variables</td><td>Univariate</td><td/><td/><td>Multivariate</td><td/><td/></tr><tr><td/><td>Odds ratio</td><td>95&#x0200a;% CI</td><td>
<italic>P</italic> value</td><td>Odds ratio</td><td>95&#x0200a;% CI</td><td>
<italic>P</italic> value</td></tr></thead><tbody><tr><td valign="middle" align="left">Female</td><td valign="middle" align="left">1.548</td><td valign="middle" align="left">0.416&#x0200a;&#x02013;&#x0200a;5.763</td><td valign="middle" align="left">0.515</td><td valign="middle" align="left"/><td valign="middle" align="left"/><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left">Naive papilla</td><td valign="middle" align="left">1.171</td><td valign="middle" align="left">0.332&#x0200a;&#x02013;&#x0200a;4.127</td><td valign="middle" align="left">0.806</td><td valign="middle" align="left"/><td valign="middle" align="left"/><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left">Difficult cannulation (&#x0003e;&#x0200a;8 attempt)</td><td valign="middle" align="left">0.890</td><td valign="middle" align="left">0.241&#x0200a;&#x02013;&#x0200a;3.281</td><td valign="middle" align="left">0.861</td><td valign="middle" align="left"/><td valign="middle" align="left"/><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left">Pancreatography (&#x0003e;&#x0200a;3 times)</td><td valign="middle" align="left">1.343</td><td valign="middle" align="left">0.382&#x0200a;&#x02013;&#x0200a;4.723</td><td valign="middle" align="left">0.646</td><td valign="middle" align="left"/><td valign="middle" align="left"/><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left">Pancreatic acinarization</td><td valign="middle" align="left">1.382</td><td valign="middle" align="left">0.334&#x0200a;&#x02013;&#x0200a;5.718</td><td valign="middle" align="left">0.656</td><td valign="middle" align="left"/><td valign="middle" align="left"/><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left">Therapeutic biliary balloon dilation</td><td valign="middle" align="left">0.941</td><td valign="middle" align="left">0.186&#x0200a;&#x02013;&#x0200a;4.760</td><td valign="middle" align="left">0.942</td><td valign="middle" align="left"/><td valign="middle" align="left"/><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left">Ampullectomy</td><td valign="middle" align="left">1.383</td><td valign="middle" align="left">0.151&#x0200a;&#x02013;&#x0200a;12.690</td><td valign="middle" align="left">0.774</td><td valign="middle" align="left"/><td valign="middle" align="left"/><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left">Placement of pancreatic stent</td><td valign="middle" align="left">0.819</td><td valign="middle" align="left">0.163&#x0200a;&#x02013;&#x0200a;4.112</td><td valign="middle" align="left">0.808</td><td valign="middle" align="left">1.042</td><td valign="middle" align="left">0.191&#x0200a;&#x02013;&#x0200a;5.684</td><td valign="middle" align="left">0.962</td></tr><tr><td valign="middle" align="left">Sphincterotomy</td><td valign="middle" align="left">1.576</td><td valign="middle" align="left">0.301&#x0200a;&#x02013;&#x0200a;8.264</td><td valign="middle" align="left">0.591</td><td valign="middle" align="left">2.533</td><td valign="middle" align="left">0.404&#x0200a;&#x02013;&#x0200a;15.884</td><td valign="middle" align="left">0.321</td></tr><tr><td valign="middle" align="left">Flurbiprofen axetil</td><td valign="middle" align="left">0.217</td><td valign="middle" align="left">0.044&#x0200a;&#x02013;&#x0200a;1.063</td><td valign="middle" align="left">0.059</td><td valign="middle" align="left">0.185</td><td valign="middle" align="left">0.036&#x0200a;&#x02013;&#x0200a;0.967</td><td valign="middle" align="left">0.046</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>This study showed that IV injection of low-dose flurbiprofen axetil immediately after ERCP reduced PEP in high-risk patients. In addition, it may reduce moderate and severe PEP. However, flurbiprofen axetil did not reduce hyperamylasemia at 2 hours after ERCP. In this study, the NNT to prevent PEP in high-risk patients was 7.9. This was similar to a previous study of rectal NSAIDs use <xref rid="JR398-6" ref-type="bibr">6</xref>.</p><p>IV injection of 50&#x0200a;mg flurbiprofen axetil immediately after ERCP reduced PEP in high-risk patients. There are several hypotheses regarding the mechanism of PEP, and the promoters that lead to PEP are not fully understood although the mechanisms are believed to be multifactorial <xref rid="JR398-4" ref-type="bibr">4</xref>
<xref rid="JR398-18" ref-type="bibr">18</xref>. One such factor is the patient&#x02019;s inflammatory reaction to irritation of the pancreatic duct, in which ERCP plays a role <xref rid="JR398-19" ref-type="bibr">19</xref>
<xref rid="JR398-20" ref-type="bibr">20</xref>
<xref rid="JR398-21" ref-type="bibr">21</xref>. NSAIDs are potent inhibitors of phospholipase A2, cyclooxygenase, and neutrophil&#x02013;endothelial interactions, all of which are involved in inflammation of the pancreatic duct. Thus, it is believed that NSAID administration may be of benefit in preventing pancreatitis. Several meta-analyses and randomized controlled trials have revealed that rectal NSAIDs are effective <xref rid="JR398-12" ref-type="bibr">12</xref>
<xref rid="JR398-13" ref-type="bibr">13</xref>
<xref rid="JR398-14" ref-type="bibr">14</xref>
<xref rid="JR398-15" ref-type="bibr">15</xref>
<xref rid="JR398-22" ref-type="bibr">22</xref>. Most of those studies adopted a dose of 100&#x0200a;mg of rectal NSAIDs, which is not suitable for Asian patients. So, Otsuka et al. reported that 50&#x0200a;mg rectally diclofenac before ERCP was effective in Asian patients <xref rid="JR398-17" ref-type="bibr">17</xref>. Although the efficacy of NSAIDs is reportedly dose-dependent <xref rid="JR398-23" ref-type="bibr">23</xref>, it is suggested that low-dose NSAIDs exert activity against PEP. However, NSAIDs were administered to all patients before ERCP in this study. Side effects are common with NSAIDs use <xref rid="JR398-6" ref-type="bibr">6</xref>, and the incidence of PEP in patients with 0 or 0.5 risk points indicated 1.9&#x0200a;% (9/463) in our institution. Therefore, we considered that NSAID administration was unnecessary for low-risk patients. PEP risk score was decided after ERCP, we made a study design to low-dose flurbiprofen injection after ERCP. Furthermore, flurbiprofen axetil was considered easier to administer than rectal NSAIDs because of its intravenous route. This study revealed that IV injection of low-dose flurbiprofen axetil was an effective, safe and easy method for the prevention of PEP.</p><p>We administered nafamostat mesilate to the patients in both groups. Nafamostat mesilate has been reported to prevent PEP <xref rid="JR398-24" ref-type="bibr">24</xref>, so administration of a protease inhibitor is strongly recommended based on Japanese guidelines <xref rid="JR398-25" ref-type="bibr">25</xref>. Therefore, it was difficult to design a study that would not include the administration of a protease inhibitor. The possibility exists that the effects of flurbiprofen axetil may be dependent on nafamostat mesilate. However, nafamostat mesilate was not considered a confounding factor because it was administered to both groups.</p><p>Flurbiprofen axetil did not reduce hyperamylasemia at 2 hours after ERCP. Hyperamylasemia is useful in the diagnosis of PEP, and LaFerla et al. reported that amylase at 2 hours after ERCP was useful for the prediction of PEP. Hyperamylasemia is thought to be caused by injury of the pancreatic duct or pancreatic parenchyma associated with ERCP. In this study, the specificity of hyperpmylasemia was 25&#x0200a;% in the flurbiprofen group and 64.3&#x0200a;% in the placebo group. The peak concentration of flurbiprofen axetil is reached 6.7 minutes after IV administration and the elimination half-time is 5.8 hours <xref rid="JR398-26" ref-type="bibr">26</xref>. This suggests that, once the pancreatic duct and pancreatic parenchyma are injured by ERCP, the progress of pancreatitis could be prevented via the rapid anti-inflammatory effect of flurbiprofen axetil, thus reducing the severity of PEP.</p><p>Flurbiprofen axetil did not reduce the incidence of PEP in the patients who had a PEP risk score of &#x02265;&#x0200a;2 points. In contrast, moderate and severe PEP did not occur in the flurbiprofen group. However, a result might change if numbers increase because there were few patients with a PEP risk score &#x02265;&#x0200a;2. We hypothesize that the incidence of PEP in the group with PEP risk scores &#x02265;&#x0200a;2 was reduced by increasing the quantity of Flurbiprofen axetil because the anti-inflammatory effect of flurbiprofen axetil effect is dose-dependent <xref rid="JR398-23" ref-type="bibr">23</xref>. Therefore, PEP cannot be prevented by flurbiprofen axetil in the group with PEP risk scores &#x02265;&#x0200a;2 but severe pancreatitis can be prevented. In the future, we plan to conduct a comparative study of low-dose and high-dose flurbiprofen axetil in patients with a PEP risk score &#x02265;&#x0200a;2.</p><p>In this study, we attempted cannulation using a conventional catheter by contrast-injection cannulation methods. If this approach failed, we attempted WGC. WGC is the preferred technique because of its association with higher cannulation rates and lower risk of PEP, as reported by Cennamo V et al <xref rid="JR398-27" ref-type="bibr">27</xref>. However, subsequent studies have reported conflicting results. Nambu et al. reported that the incidence of PEP tended to be lower with the WGC method than with contrast-injection methods, although the success rate of cannulation was comparable <xref rid="JR398-28" ref-type="bibr">28</xref>. Kawakami et al. and Kobayashi et al. reported that the WGC technique did not reduce PEP and did not improve the success rate of selective bile duct cannulation over contrast-injection methods.<xref rid="JR398-29" ref-type="bibr">29</xref>
<xref rid="JR398-30" ref-type="bibr">30</xref>. Therefore, we cannot conclude that WGC is superior to contrast-injection methods in terms of effectiveness and safety. For that reason, initial attempts at cannulation in this study were made using the contrast-injection cannulation method, with which the researchers were more familiar.</p><p>There were 3 limitations of this study. First, the study was conducted at a single center. Second, pancreatic duct stent placement was left to the discretion of the endoscopist. In this study, a pancreatic duct stent was placed where a guidewire remained following ERCP. Pancreatic stents were not placed where good discharge of the contrast agent in the pancreatic duct was observed. However, multivariate analysis showed that placement of the pancreatic stent was not significantly affected by reduced PEP (<xref rid="TB398-5" ref-type="table">Table&#x0200a;5</xref>). Third, interim analysis was not preplanned. As this was a single-blind study, we found that in the first 100 patients, administration of flurbiprofen reduced PEP, and an interim analysis showed its usefulness. Because PEP has been demonstrated to be a fatal complication, we stopped this prospective study. Further multicenter study will be required to determine the efficacy of flurbiprofen.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>In conclusion, IV injection of low-dose flurbiprofen axetil in high-risk patients is an effective, safe and easy method in the prevention of PEP.</p></sec></body><back><fn-group><fn id="d31e154" fn-type="conflict"><p>
<bold>Competing interests:</bold> None</p></fn></fn-group><ref-list><title>References</title><ref id="JR398-1"><label>1</label><mixed-citation publication-type="journal"><name><surname>Cotton</surname><given-names>P B</given-names></name><name><surname>Lehman</surname><given-names>G</given-names></name><name><surname>Vennes</surname><given-names>J</given-names></name><etal/><article-title>Endoscopic sphincterotomy complications and their management: an attempt at consensus</article-title><source>Gastrointest Endosc</source><year>1991</year><volume>37</volume><fpage>3 83</fpage><lpage>393</lpage></mixed-citation></ref><ref id="JR398-2"><label>2</label><mixed-citation publication-type="journal"><name><surname>Freeman</surname><given-names>M L</given-names></name><name><surname>Nelson</surname><given-names>D B</given-names></name><name><surname>Sherman</surname><given-names>S</given-names></name><etal/><article-title>Complications of endoscopic biliary sphincterotomy</article-title><source>N Engl J Med</source><year>1996</year><volume>335</volume><fpage>909</fpage><lpage>918</lpage><pub-id pub-id-type="pmid">8782497</pub-id></mixed-citation></ref><ref id="JR398-3"><label>3</label><mixed-citation publication-type="journal"><name><surname>Freeman</surname><given-names>M L</given-names></name><name><surname>DiSario</surname><given-names>J A</given-names></name><name><surname>Nelson</surname><given-names>D B</given-names></name><etal/><article-title>Risk factors for post-ERCP pancreatitis: a prospective, multicenter study</article-title><source>Gastrointest Endosc</source><year>2001</year><volume>54</volume><fpage>425</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">11577302</pub-id></mixed-citation></ref><ref id="JR398-4"><label>4</label><mixed-citation publication-type="journal"><name><surname>Gottlieb</surname><given-names>K</given-names></name><name><surname>Sherman</surname><given-names>S</given-names></name><article-title>ERCP and endoscopic biliary sphincterotomy-induced pancreatitis</article-title><source>Gastrointest Endosc Clin N Am</source><year>1998</year><volume>8</volume><fpage>87</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">9405753</pub-id></mixed-citation></ref><ref id="JR398-5"><label>5</label><mixed-citation publication-type="journal"><name><surname>Freeman</surname><given-names>M L</given-names></name><article-title>Adverse outcomes of ERCP</article-title><source>Gastrointest Endosc</source><year>2002</year><volume>56</volume><fpage>273</fpage><lpage>282</lpage></mixed-citation></ref><ref id="JR398-6"><label>6</label><mixed-citation publication-type="journal"><name><surname>Elmunzer</surname><given-names>B J</given-names></name><name><surname>Scheiman</surname><given-names>J M</given-names></name><name><surname>Lehman</surname><given-names>G A</given-names></name><etal/><article-title>A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>1414</fpage><lpage>1422</lpage><pub-id pub-id-type="pmid">22494121</pub-id></mixed-citation></ref><ref id="JR398-7"><label>7</label><mixed-citation publication-type="journal"><name><surname>Rabenstein</surname><given-names>T</given-names></name><name><surname>Hahn</surname><given-names>E G</given-names></name><article-title>Post-ERCP pancreatitis: new momentum</article-title><source>Endoscopy</source><year>2002</year><volume>34</volume><fpage>325</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">11932791</pub-id></mixed-citation></ref><ref id="JR398-8"><label>8</label><mixed-citation publication-type="journal"><name><surname>Vandervoort</surname><given-names>J</given-names></name><name><surname>Soetikno</surname><given-names>R M</given-names></name><name><surname>Tham</surname><given-names>T C</given-names></name><etal/><article-title>Risk factors for complications after performance of ERCP</article-title><source>Gastrointest Endosc</source><year>2002</year><volume>56</volume><fpage>652</fpage><lpage>656</lpage><pub-id pub-id-type="pmid">12397271</pub-id></mixed-citation></ref><ref id="JR398-9"><label>9</label><mixed-citation publication-type="journal"><name><surname>Whitcomb</surname><given-names>D C</given-names></name><article-title>Acute pancreatitis: molecular biology update</article-title><source>J Gastrointest Surg</source><year>2003</year><volume>7</volume><fpage>940</fpage><lpage>942</lpage><pub-id pub-id-type="pmid">14675701</pub-id></mixed-citation></ref><ref id="JR398-10"><label>10</label><mixed-citation publication-type="journal"><name><surname>Gross</surname><given-names>V</given-names></name><name><surname>Leser</surname><given-names>H G</given-names></name><name><surname>Heinisch</surname><given-names>A</given-names></name><etal/><article-title>Inflammatory mediators and cytokines: new aspects of the pathophysiology and assessment of severity of acute pancreatitis?</article-title><source>Hepatogastroenterology</source><year>1993</year><volume>40</volume><fpage>522</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">7509768</pub-id></mixed-citation></ref><ref id="JR398-11"><label>11</label><mixed-citation publication-type="journal"><name><surname>M&#x000e4;kel&#x000e4;</surname><given-names>A</given-names></name><name><surname>Kuusi</surname><given-names>T</given-names></name><name><surname>Schr&#x000f6;der</surname><given-names>T</given-names></name><article-title>Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro</article-title><source>Scand J Clin Lab Invest</source><year>1997</year><volume>57</volume><fpage>401</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">9279965</pub-id></mixed-citation></ref><ref id="JR398-12"><label>12</label><mixed-citation publication-type="journal"><name><surname>Murray</surname><given-names>B</given-names></name><name><surname>Carter</surname><given-names>R</given-names></name><name><surname>Imrie</surname><given-names>C</given-names></name><etal/><article-title>Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography</article-title><source>Gastroenterology</source><year>2003</year><volume>124</volume><fpage>1786</fpage><lpage>1791</lpage><pub-id pub-id-type="pmid">12806612</pub-id></mixed-citation></ref><ref id="JR398-13"><label>13</label><mixed-citation publication-type="journal"><name><surname>Sotoudehmanesh</surname><given-names>R</given-names></name><name><surname>Khatibian</surname><given-names>M</given-names></name><name><surname>Kolahdoozan</surname><given-names>S</given-names></name><etal/><article-title>Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP</article-title><source>Am J Gastroenterol</source><year>2007</year><volume>102</volume><fpage>978</fpage><lpage>983</lpage><pub-id pub-id-type="pmid">17355281</pub-id></mixed-citation></ref><ref id="JR398-14"><label>14</label><mixed-citation publication-type="journal"><name><surname>Khoshbaten</surname><given-names>M</given-names></name><name><surname>Khorram</surname><given-names>H</given-names></name><name><surname>Madad</surname><given-names>L</given-names></name><etal/><article-title>Role of diclofenac in reducing postendoscopic retrograde cholangiopancreatography pancreatitis</article-title><source>J Gastroenterol Hepatol</source><year>2008</year><volume>23</volume><fpage>e11</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">17683501</pub-id></mixed-citation></ref><ref id="JR398-15"><label>15</label><mixed-citation publication-type="journal"><name><surname>Monta&#x000f1;o Loza</surname><given-names>A</given-names></name><name><surname>Rodr&#x000ed;guez Lomel&#x000ed;</surname><given-names>X</given-names></name><name><surname>Garc&#x000ed;a Correa</surname><given-names>J E</given-names></name><etal/><article-title>Effect of the administration of rectal indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes</article-title><source>Rev Esp Enferm Dig</source><year>2007</year><volume>99</volume><fpage>330</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">17883296</pub-id></mixed-citation></ref><ref id="JR398-16"><label>16</label><mixed-citation publication-type="journal"><name><surname>Elmunzer</surname><given-names>B J</given-names></name><name><surname>Higgins</surname><given-names>P D</given-names></name><name><surname>Saini</surname><given-names>S D</given-names></name><etal/><article-title>Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data</article-title><source>Am J Gastroenterol</source><year>2012</year><volume>108</volume><fpage>410</fpage><lpage>415</lpage></mixed-citation></ref><ref id="JR398-17"><label>17</label><mixed-citation publication-type="journal"><name><surname>Otsuka</surname><given-names>T</given-names></name><name><surname>Kawazoe</surname><given-names>S</given-names></name><name><surname>Nakashita</surname><given-names>S</given-names></name><etal/><article-title>Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial</article-title><source>J Gastroenterol</source><year>2012</year><volume>47</volume><fpage>912</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">22350703</pub-id></mixed-citation></ref><ref id="JR398-18"><label>18</label><mixed-citation publication-type="journal"><name><surname>Hofbauer</surname><given-names>B</given-names></name><name><surname>Saluja</surname><given-names>A K</given-names></name><name><surname>Lerch</surname><given-names>M M</given-names></name><etal/><article-title>Intra-acinar cell activation of trypsinogen during cerulean-induced pancreatitis in rats</article-title><source>Am J Physiol</source><year>1998</year><volume>275</volume><fpage>G352</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">9688663</pub-id></mixed-citation></ref><ref id="JR398-19"><label>19</label><mixed-citation publication-type="journal"><name><surname>Messmann</surname><given-names>H</given-names></name><name><surname>Vogt</surname><given-names>W</given-names></name><name><surname>Holstege</surname><given-names>A</given-names></name><etal/><article-title>Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis</article-title><source>Gut</source><year>1997</year><volume>40</volume><fpage>80</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">9155580</pub-id></mixed-citation></ref><ref id="JR398-20"><label>20</label><mixed-citation publication-type="journal"><name><surname>Karne</surname><given-names>S</given-names></name><name><surname>Gorelick</surname><given-names>F S</given-names></name><article-title>Etiopathogenesis of acute pancreatitis</article-title><source>Surg Clin N Am</source><year>1999</year><volume>79</volume><fpage>699</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">10470320</pub-id></mixed-citation></ref><ref id="JR398-21"><label>21</label><mixed-citation publication-type="journal"><name><surname>Bhatia</surname><given-names>M</given-names></name><name><surname>Brady</surname><given-names>M</given-names></name><name><surname>Shokuhi</surname><given-names>S</given-names></name><etal/><article-title>Inflammatory mediators in acute pancreatitis</article-title><source>J Pathol</source><year>2000</year><volume>190</volume><fpage>117</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">10657008</pub-id></mixed-citation></ref><ref id="JR398-22"><label>22</label><mixed-citation publication-type="journal"><name><surname>Elmunzer</surname><given-names>B J</given-names></name><name><surname>Waljee</surname><given-names>A K</given-names></name><name><surname>Elta</surname><given-names>G H</given-names></name><etal/><article-title>A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis</article-title><source>Gut</source><year>2008</year><volume>57</volume><fpage>1262</fpage><lpage>1267</lpage><pub-id pub-id-type="pmid">18375470</pub-id></mixed-citation></ref><ref id="JR398-23"><label>23</label><mixed-citation publication-type="journal"><name><surname>Giagoudakis</surname><given-names>G</given-names></name><name><surname>Markantonis</surname><given-names>S L</given-names></name><article-title>Relationships between the concentrations of prostaglandins and the nonsteroidal anti-inflammatory drugs indomethacin, diclofenac, and ibuprofen</article-title><source>Pharmacotherapy</source><year>2005</year><volume>25</volume><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">15767216</pub-id></mixed-citation></ref><ref id="JR398-24"><label>24</label><mixed-citation publication-type="journal"><name><surname>Yuhara</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name><name><surname>Kawaguchi</surname><given-names>Y</given-names></name><etal/><article-title>Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis</article-title><source>J Gastroenterol</source><year>2014</year><volume>49</volume><fpage>388</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">23720090</pub-id></mixed-citation></ref><ref id="JR398-25"><label>25</label><mixed-citation publication-type="journal"><collab><italic>Working Group JPS</italic>
</collab><article-title>Post ERCP Pancreatitis Guidelines 2015</article-title><source>Suizou</source><volume>30</volume><fpage>539</fpage><lpage>584</lpage></mixed-citation></ref><ref id="JR398-26"><label>26</label><mixed-citation publication-type="journal"><name><surname>Higashino</surname><given-names>M</given-names></name><name><surname>Konishi</surname><given-names>Y</given-names></name><name><surname>Kojima</surname><given-names>H</given-names></name><etal/><article-title>83 single and human blood concentration at the time of continuous intravenous administration transition and metabolism</article-title><source>Kiso to Rinsho</source><year>1992</year><volume>26</volume><fpage>3907</fpage><lpage>3921</lpage></mixed-citation></ref><ref id="JR398-27"><label>27</label><mixed-citation publication-type="journal"><name><surname>Cennamo</surname><given-names>V</given-names></name><name><surname>Fuccio</surname><given-names>L</given-names></name><name><surname>Zagari</surname><given-names>R M</given-names></name><etal/><article-title>Can a wire-guided cannulation technique increase bile duct cannulation rate and prevent post-ERCP pancreatitis? A meta-analysis of randomized controlled trials</article-title><source>Am J Gastroenterol</source><year>2009</year><volume>104</volume><fpage>2343</fpage><lpage>2350</lpage><pub-id pub-id-type="pmid">19532133</pub-id></mixed-citation></ref><ref id="JR398-28"><label>28</label><mixed-citation publication-type="journal"><name><surname>Nambu</surname><given-names>T</given-names></name><name><surname>Ukita</surname><given-names>T</given-names></name><name><surname>Shigoka</surname><given-names>H</given-names></name><etal/><article-title>Wire-guided selective cannulation of the bile duct with a sphincterotome: a prospective randomized comparative study with the standard method</article-title><source>Scand J Gastroenterol</source><year>2011</year><volume>46</volume><fpage>109</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">20923377</pub-id></mixed-citation></ref><ref id="JR398-29"><label>29</label><mixed-citation publication-type="journal"><name><surname>Kawakami</surname><given-names>H</given-names></name><name><surname>Maguchi</surname><given-names>H</given-names></name><name><surname>Mukai</surname><given-names>T</given-names></name><etal/><article-title>A multicenter, prospective, randomized study of selective bile duct cannulation performed by multiple endoscopists: the BIDMEN study</article-title><source>Gastrointest Endosc</source><year>2012</year><volume>75</volume><fpage>362</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">22248605</pub-id></mixed-citation></ref><ref id="JR398-30"><label>30</label><mixed-citation publication-type="journal"><name><surname>Kobayashi</surname><given-names>G</given-names></name><name><surname>Fujita</surname><given-names>N</given-names></name><name><surname>Imaizumi</surname><given-names>K</given-names></name><etal/><article-title>Wire-guided biliary cannulation technique does not reduce the risk of post-ERCP pancreatitis: multicenter randomized controlled trial</article-title><source>Dig Endosc</source><year>2013</year><volume>25</volume><fpage>295</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">23368891</pub-id></mixed-citation></ref></ref-list></back></article>